These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 34427065)
1. Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study. Cho Y; Sohn Y; Hyun J; Baek Y; Kim M; Kim J; Ahn J; Jeong S; Ku N; Yeom JS; Ahn M; Oh D; Choi J; Kim S; Lee K; Song Y; Choi J Yonsei Med J; 2021 Sep; 62(9):799-805. PubMed ID: 34427065 [TBL] [Abstract][Full Text] [Related]
2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
3. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428 [TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial. Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167 [TBL] [Abstract][Full Text] [Related]
6. Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study. Hoepler WP; Weidner L; Traugott MT; Neuhold S; Meyer EL; Zoufaly A; Seitz T; Kitzberger R; Baumgartner S; Pawelka E; Karolyi M; Grieb A; Hind J; Laferl H; Friese E; Wenisch C; Aberle SW; Aberle JH; Weseslindtner L; Jungbauer C Infect Dis (Lond); 2021 Nov; 53(11):820-829. PubMed ID: 34128763 [TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients. Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535 [No Abstract] [Full Text] [Related]
8. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19. Liu M; Chen Z; Dai MY; Yang JH; Chen XB; Chen D; You H; Guo X; Leng Y; Yu L; Zhang ML; Wu X; Yang J; Gao C; Tenen DG; Chai L; Ai F Transfusion; 2020 Oct; 60(10):2210-2216. PubMed ID: 32770691 [TBL] [Abstract][Full Text] [Related]
9. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927 [TBL] [Abstract][Full Text] [Related]
10. Convalescent plasma therapy in patients with COVID-19. Altuntas F; Ata N; Yigenoglu TN; Bascı S; Dal MS; Korkmaz S; Namdaroglu S; Basturk A; Hacıbekiroglu T; Dogu MH; Berber İ; Dal K; Kınık K; Haznedaroglu İ; Yılmaz FM; Kılıç İ; Demircioğlu S; Yosunkaya A; Erkurt MA; Turgut B; Caglayan M; Celik O Transfus Apher Sci; 2021 Feb; 60(1):102955. PubMed ID: 33011076 [TBL] [Abstract][Full Text] [Related]
11. Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study. Ghadami L; Hasibi M; Asadollahi-Amin A; Asanjarani B; Farahmand M; Abdollahi H Microb Pathog; 2022 Apr; 165():105482. PubMed ID: 35288278 [TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]